251 related articles for article (PubMed ID: 24277078)
1. Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome.
Kolyada A; Porter A; Beglova N
Blood; 2014 Feb; 123(7):1090-7. PubMed ID: 24277078
[TBL] [Abstract][Full Text] [Related]
2. Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome.
Kolyada A; Ke Q; Karageorgos I; Mahlawat P; Barrios DA; Kang PM; Beglova N
J Thromb Haemost; 2016 Jun; 14(6):1298-307. PubMed ID: 26990752
[TBL] [Abstract][Full Text] [Related]
3. An A1-A1 mutant with improved binding and inhibition of β2GPI/antibody complexes in antiphospholipid syndrome.
Kolyada A; Karageorgos I; Mahlawat P; Beglova N
FEBS J; 2015 Mar; 282(5):864-73. PubMed ID: 25546421
[TBL] [Abstract][Full Text] [Related]
4. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome.
Lopez D; Kobayashi K; Merrill JT; Matsuura E; Lopez LR
Clin Dev Immunol; 2003; 10(2-4):203-11. PubMed ID: 14768953
[TBL] [Abstract][Full Text] [Related]
5. Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome.
Matsuura E; Kobayashi K; Hurley BL; Lopez LR
Lupus; 2006; 15(7):478-83. PubMed ID: 16898186
[TBL] [Abstract][Full Text] [Related]
6. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
7. [Anti-beta2 glycoprotein I-beta2 glycoprotein I] immune complexes in patients with antiphospholipid syndrome and other autoimmune diseases.
Biasiolo A; Rampazzo P; Brocco T; Barbero F; Rosato A; Pengo V
Lupus; 1999; 8(2):121-6. PubMed ID: 10192506
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of purified anti-β2GPI IgG N-glycosylation associate with thrombotic, obstetric and catastrophic antiphospholipid syndrome.
Liu T; Han J; Zhang R; Tang Z; Yi G; Gong W; Wan L; Hu Q; Teng J; Liu H; Cheng X; Ye J; Su Y; Sun Y; Shi Y; Gu J; Ren S; Yang C; Shi H
Rheumatology (Oxford); 2022 Mar; 61(3):1243-1254. PubMed ID: 34015111
[TBL] [Abstract][Full Text] [Related]
10. A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome.
Kolyada A; Lee CJ; De Biasio A; Beglova N
PLoS One; 2010 Dec; 5(12):e15345. PubMed ID: 21179511
[TBL] [Abstract][Full Text] [Related]
11. The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome.
Patsouras M; Tsiki E; Karagianni P; Vlachoyiannopoulos PG
J Autoimmun; 2020 Dec; 115():102527. PubMed ID: 32709480
[TBL] [Abstract][Full Text] [Related]
12. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice.
Ostertag MV; Liu X; Henderson V; Pierangeli SS
Lupus; 2006; 15(6):358-65. PubMed ID: 16830882
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome.
Arvieux J; Renaudineau Y; Mane I; Perraut R; Krilis SA; Youinou P
Thromb Haemost; 2002 Apr; 87(4):599-605. PubMed ID: 12008941
[TBL] [Abstract][Full Text] [Related]
14. TLR4 is involved in the pathogenic effects observed in a murine model of antiphospholipid syndrome.
Xie H; Kong X; Zhou H; Xie Y; Sheng L; Wang T; Xia L; Yan J
Clin Immunol; 2015 Oct; 160(2):198-210. PubMed ID: 26065621
[TBL] [Abstract][Full Text] [Related]
15. Both IgG and IgM anti-beta2 glycoprotein I antibodies assays are clinically useful to the antiphospholipid syndrome diagnosis.
Li R; Daguzan M; Vandermijnsbrugge F; Gyling M; Cantinieaux B
Acta Clin Belg; 2014 Dec; 69(6):433-8. PubMed ID: 25103595
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome.
Mahler M; Albesa R; Zohoury N; Bertolaccini ML; Ateka-Barrutia O; Rodriguez-Garcia JL; Norman GL; Khamashta M
Lupus; 2016 Jul; 25(8):911-6. PubMed ID: 27252269
[TBL] [Abstract][Full Text] [Related]
17. β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome.
Tanimura K; Jin H; Suenaga T; Morikami S; Arase N; Kishida K; Hirayasu K; Kohyama M; Ebina Y; Yasuda S; Horita T; Takasugi K; Ohmura K; Yamamoto K; Katayama I; Sasazuki T; Lanier LL; Atsumi T; Yamada H; Arase H
Blood; 2015 Apr; 125(18):2835-44. PubMed ID: 25733579
[TBL] [Abstract][Full Text] [Related]
18. Biosensor analysis of beta2-glycoprotein I-reactive autoantibodies: evidence for isotype-specific binding and differentiation of pathogenic from infection-induced antibodies.
Metzger J; von Landenberg P; Kehrel M; Buhl A; Lackner KJ; Luppa PB
Clin Chem; 2007 Jun; 53(6):1137-43. PubMed ID: 17434906
[TBL] [Abstract][Full Text] [Related]
19. Antiphospholipid syndrome: 30 years and our contribution.
Koike T
Int J Rheum Dis; 2015 Feb; 18(2):233-41. PubMed ID: 25524556
[TBL] [Abstract][Full Text] [Related]
20. Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome.
Takeuchi R; Atsumi T; Ieko M; Amasaki Y; Ichikawa K; Koike T
Br J Haematol; 2002 Dec; 119(3):781-8. PubMed ID: 12437660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
